Massachusetts Financial Services Co. MA Has $13.54 Million Stock Holdings in Immunocore Holdings plc (NASDAQ:IMCR)

Massachusetts Financial Services Co. MA decreased its position in Immunocore Holdings plc (NASDAQ:IMCR) by 7.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 459,045 shares of the company’s stock after selling 39,176 shares during the period. Massachusetts Financial Services Co. MA owned about 0.92% of Immunocore worth $13,542,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of IMCR. Wellington Management Group LLP grew its holdings in shares of Immunocore by 10.5% in the 3rd quarter. Wellington Management Group LLP now owns 7,048,833 shares of the company’s stock valued at $219,430,000 after acquiring an additional 668,382 shares in the last quarter. Groupama Asset Managment acquired a new position in Immunocore during the fourth quarter valued at approximately $17,700,000. Primecap Management Co. CA grew its stake in Immunocore by 8.0% in the fourth quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock valued at $78,722,000 after purchasing an additional 196,530 shares in the last quarter. Principal Financial Group Inc. grew its stake in Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock valued at $17,007,000 after purchasing an additional 109,206 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Immunocore by 7,437.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock worth $2,872,000 after purchasing an additional 91,033 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company’s stock.

Immunocore Stock Performance

NASDAQ:IMCR opened at $26.28 on Tuesday. The stock has a 50 day simple moving average of $29.68 and a 200 day simple moving average of $30.72. The stock has a market cap of $1.31 billion, a P/E ratio of -27.66 and a beta of 0.75. Immunocore Holdings plc has a 1-year low of $24.84 and a 1-year high of $63.94. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Wall Street Analyst Weigh In

Several research firms recently weighed in on IMCR. HC Wainwright reissued a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Morgan Stanley reissued an “equal weight” rating and issued a $35.00 price objective on shares of Immunocore in a research report on Friday, March 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 target price on shares of Immunocore in a report on Wednesday, March 12th. Finally, Mizuho reduced their price target on Immunocore from $38.00 to $33.00 and set a “neutral” rating for the company in a report on Monday. One analyst has rated the stock with a sell rating, four have issued a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $65.18.

Insider Transactions at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the transaction, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 9.10% of the company’s stock.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.